← Ablatotech Vitals
Hematology EvidenceDigest

Advancements in Targeted Therapies for Relapsed/Refractory Large B-Cell Lymphoma Post-CAR T-cell Failure

Hematology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
November 17, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Relapsed or refractory large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy remains a significant clinical challenge with limited standard options. Emerging targeted therapies, including novel antibody-drug conjugates, bispecific antibodies, and small molecule inhibitors, show promise in this setting but require further validation. Radiotherapy may have a role as a salvage or bridging strategy post-CAR T failure. Current evidence supports a personalized approach integrating these modalities, guided by molecular profiling and patient fitness, to improve outcomes in this difficult-to-treat population (Nagler et al., 2023; Weiss et al., 2025).

Clinical bottom line

Relapsed or refractory large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy remains a significant clinical challenge with limited standard options. Emerging targeted therapies, including novel antibody-drug conjugates, bispecific antibodies, and small molecule inhibitors, show promise in this setting but require further validation. Radiotherapy may have a role as a salvage or bridging strategy post-CAR T failure. Current evidence supports a personalized approach integrating these modalities, guided by molecular profiling and patient fitness, to improve outcomes in this difficult-to-treat population (Nagler et al., 2023; Weiss et al., 2025).

What the evidence shows

CAR T-cell therapy targeting CD19 has revolutionized treatment for relapsed/refractory aggressive LBCL, but up to 50% of patients experience disease progression or relapse after treatment (Nagler et al., 2023). Management of these patients is complex due to limited approved salvage options and heterogeneous resistance mechanisms.

Recent molecular insights highlight pathways driving CAR T resistance, including antigen loss, immune evasion, and tumor microenvironment factors, suggesting targeted agents may overcome these barriers (Weiss et al., 2025). Bispecific antibodies engaging CD3 and CD20 or CD19 have demonstrated encouraging response rates in early-phase trials post-CAR T failure, offering an off-the-shelf immunotherapy alternative (Nagler et al., 2023).

Antibody-drug conjugates targeting CD79b or CD19 provide cytotoxic payload delivery with manageable toxicity profiles and have shown activity in relapsed LBCL, including post-CAR T relapse (Weiss et al., 2025). Small molecule inhibitors targeting BCL2, BTK, or epigenetic regulators are under investigation to address specific resistance pathways identified by molecular profiling.

Radiotherapy, traditionally used for localized relapse, is increasingly recognized as a salvage or bridging option post-CAR T failure, potentially enhancing local control and systemic immune responses (Review for "The Role of Radiotherapy..." 2025). However, optimal timing, dosing, and patient selection criteria remain undefined.

Caveats and uncertainty

Most data on targeted therapies post-CAR T failure derive from early-phase or retrospective studies with small cohorts, limiting generalizability. The heterogeneity of resistance mechanisms and patient comorbidities complicate standardized treatment algorithms. Long-term safety and durability of responses to novel agents remain to be established.

Radiotherapy’s role is supported mainly by systematic literature reviews and expert opinion rather than prospective trials, underscoring the need for controlled studies to clarify its benefit and integration with systemic therapies (Review for "The Role of Radiotherapy..." 2025).

Biomarker-driven approaches to select targeted agents are promising but not yet routine in clinical practice, requiring further validation in prospective cohorts.

How this may change practice

Clinicians managing relapsed/refractory LBCL after CAR T-cell therapy should consider a multidisciplinary approach incorporating molecular profiling to identify actionable targets. Emerging bispecific antibodies and antibody-drug conjugates may become preferred salvage options as more data mature.

Radiotherapy should be considered for localized relapse or as a bridging strategy, especially in patients with limited systemic options, while awaiting or complementing targeted therapies.

Ongoing clinical trials and real-world evidence will refine sequencing and combination strategies, emphasizing personalized treatment plans balancing efficacy and tolerability.


References

  1. Nagler Arnon, et al. How I treat refractory/relapsed diffuse large B‐cell lymphomas with <scp>CD19</scp>‐directed <scp>chimeric antigen receptor</scp> T cells. British Journal of Haematology. 2023.
  2. Weiss J, et al. Molecular Pathways and Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). Cancers 2025;17:DOI:10.3390/cancers17142314
  3. , et al. Review for "The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review". 2025 DOI:10.1177/15330338251351065/v1/review1

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team